Biolife4D Stock
BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality.
Sign up today and learn more about Biolife4D Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Biolife4D Stock
BIOLIFE4D is committed to perfecting the technology to make viable organ replacement a safe, accessible and affordable reality. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting and the patientâs own cells, eliminating the challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
Press
renaissancecapital - Apr, 20 2023
Synthetic heart developer BIOLIFE4D slashes unit offering by 64% ahead of $8 million IPOdigitaltrends - Sep, 17 2019
Biotech company 3D-prints a miniature human heart from stem cellsmarkets - Sep, 17 2019
BIOLIFE4D Launches Second Regulation A+ (Mini-IPO) Offering Due to Popular DemandForbes - Sep, 9 2019
BIOLIFE4D Just 3D Printed A Human âMini-HeartâEquityZen Recognized As:
